Table 3.
Cox proportional hazards regression for overall and cancer-specific mortality of leiomyosarcoma and carcinosarcoma in the 1:1 propensity score matching sample
| Leiomyosarcoma (n = 180) | Carcinosarcoma (n = 856) | |||||||
|---|---|---|---|---|---|---|---|---|
| Overall b | Cancer-specific c | Overall b | Cancer-specific c | |||||
| Variables | HR (95% CI) | P-value | aHR (95% CI) | P-value | HR (95% CI) | P-value | aHR (95% CI) | P-value |
| Adjuvant radiotherapy | ||||||||
| No treatment | reference | reference | reference | reference | ||||
| EBRT alone | 0.71 (0.33, 1.54) | 0.386 | 0.69 (0.27, 1.79) | 0.447 | 0.65 (0.45, 0.93) | 0.020 | 0.78 (0.50, 1.22) | 0.274 |
| Brachytherapy alone | 0.68 (0.14, 3.30) | 0.633 | 0.45 (0.05, 3.93) | 0.469 | 0.62 (0.40, 0.95) | 0.029 | 0.60 (0.34, 1.05) | 0.074 |
| Combination radiotherapy a | NA | NA | NA | NA | 0.47 (0.26, 0.85) | 0.013 | 0.67 (0.33, 1.33) | 0.250 |
aHR adjusted hazard ratio, CI confidence interval, EBRT external beam radiation therapy
aCombination radiotherapy: combination of EBRT and either radioactive implants or radioisotopes
bUnivariate regression model
cRace was adjusted for in multivariate regression model
NA: not available because no patient died during the study period
Unknown data for adjuvant radiotherapy were not shown in the table
Bold text indicates a significant difference with a p-value less than 0.05 compared to the reference group